Shenzhen Salubris Pharmaceuticals (002294.SZ): Self-developed innovative drug SAL0145 injection approved to conduct MASH indication clinical trials.
Xinlitai (002294.SZ) announced that the company has recently received the "Notice of Clinical Trial Approval" issued by the National Medical Products Administration, approving the company's independently developed innovative drug SAL0145 injection (project code: SAL0145) to conduct clinical trials for MASH indications.
Shenzhen Salubris Pharmaceuticals (002294.SZ) announced that they have recently received the approval notification for clinical trial from the National Medical Products Administration, allowing the company to conduct clinical trials for their innovative drug SAL0145 injection (project code: SAL0145) for the treatment of MASH indications.
SAL0145 is a siRNA drug developed by the company with independent intellectual property rights. Preclinical studies have shown its potential for treating MASH. If successfully developed and approved for market, it is expected to provide new treatment options for more patients, meet unmet clinical needs, and further enrich the company's innovative product pipeline in the field of chronic diseases.
Related Articles
CISI FIN (06058) obtained a non-committed loan financing of USD 30 million.
PLAYMATES TOYS (00869) spent HK$207,600 to repurchase 520,000 shares on March 24th.
The total principal amount of the CISI FIN(06058) affiliated purchase of notes is $10,022,000.
CISI FIN (06058) obtained a non-committed loan financing of USD 30 million.
PLAYMATES TOYS (00869) spent HK$207,600 to repurchase 520,000 shares on March 24th.
The total principal amount of the CISI FIN(06058) affiliated purchase of notes is $10,022,000.
